bcma bispecifics as maitenance in myeloma

Created using ChatSlide

This session explores the transformative role of BCMA bispecifics in myeloma treatment, covering mechanisms, clinical evidence, and practical implementation. We’ll delve into maintenance therapy, key trials, and patient selection criteria while addressing challenges like adverse effects. Through expert panel discussions, we aim to provide insights into optimizing outcomes and advancing research for improved patient care.